Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2023 Oct 16;23(1):417.
doi: 10.1186/s12886-023-03134-6.

Incidence of Nd:YAG laser capsulotomy following cataract surgery: a population-based nation-wide study - FreYAG1 study

Antoine P Brézin  1 , Antoine Labbe  2 , Cédric Schweitzer  3 , François Lignereux  4 , Pascal Rozot  5 , Mélanie Goguillot  6 , Françoise Bugnard  6 , Corinne Dot  7
Affiliations
Observational Study

Incidence of Nd:YAG laser capsulotomy following cataract surgery: a population-based nation-wide study - FreYAG1 study

Antoine P Brézin et al. BMC Ophthalmol. .

Abstract

Rationale: Nd:YAG (neodymium:yttrium-aluminum-garnet) capsulotomy (Nd:YAG-caps) is the gold standard for the treatment of PCO (Posterior Capsule Opacification). There is a lack of real-world data about Nd:YAG-caps use.

Purpose: This study's objectives were to estimate Nd:YAG-caps incidence in France, to describe the patient characteristics, and to analyze the time between surgeries and capsulotomies.

Setting: The study was based on data extracted from the EGB database, a 1/97th sample representative of the French population.

Design: observational, retrospective, cohort study using national claims data.

Methods: French adult patients who underwent Nd:YAG-caps between 2014 and 2017 were selected. Main outcomes were the number of patients and procedures performed and the risk factors associated with early Nd:YAG-caps.

Results: During the study period, Nd:YAG-caps were performed in 8,425 patients accounting for 10,774 procedures. The extrapolation to the French population led to estimate that 253.103 patients had Nd:YAG-caps, representing 312.103 procedures in 2017. The mean age at Nd:YAG-caps was 75.1 (± 10.2) years. About 36% of patients presented at least one ocular comorbidity. Nd:YAG-caps was performed within 2 years after surgery in 33.0% of patients and within one year in 9.8% of patients. Patients with Nd:YAG-caps within the first year (OR CI95 0.721 [0.673-0.772]) or in the first two years (OR CI95 0.721 [0.673-0.772]) were younger than patients with later Nd:YAG-caps and had a more frequent history of treated ocular diseases (OR 1.516 and 1.178, respectively).

Conclusions: This study brought new real-world and large-scale data regarding Nd:YAG-caps use and gave an updated insight into the patients' characteristics.

Keywords: Cataract; Dataclaims; Epidemiology; Nd:YAG; Ophthalmology.

PubMed Disclaimer

Conflict of interest statement

A Brézin is a consultant for Alcon; A Labbé is a consultant for Alcon, Allergan, Bausch & Lomb, Glaukos, Santen, Théa and Horus Pharma; C Schweiter has had advisory and honoraria for lecturing with Alcon, Allergan, Bausch & Lomb, Glaukos, Horus, Johnson & Johnson, Nicox, Théa; F Lignereux is consultant for Alcon and J&J; P Rozot is consultant for Alcon, Carl Zeiss Meditec, Horus Pharma, Hoya, Johnson & Johnson, Thea; M Goguillot and F Bugnard are employees of stève consultants, which has a research consultancy contract with Alcon; C Dot is consultant for Abbvie, Alcon, Bayer, Horus Pharma, Hoya, Novartis, Roche, Zeiss.

Figures

Fig. 1
Fig. 1
Patient Disposition over study period (January 1st, 2014 – December 31st, 2017)
Fig. 2
Fig. 2
Number of Patients (a) and Standardized rate per 100,000 inhabitants (b) of Patients with Nd:YAG-caps Procedure – Year 2017 (N = 2,550)
Fig. 3
Fig. 3
Proportion of patients with a history of glaucoma or treated diabetic ocular disorder among patients with Nd:YAG-caps procedure within or after 1-year post cataract surgery (N = 7,462)
See this image and copyright information in PMC

References

    1. Caisse Nationale d’Assurance Maladie. Actes techniques de la CCAM en 2021 | L’Assurance Maladie. https://assurance-maladie.ameli.fr/etudes-et-donnees/actes-techniques-cc.... Accessed 5 Oct 2022.
    1. Agence Technique de l’Information sur l’Hospitalisation. Open CCAM 2021 | Stats ATIH. https://www.scansante.fr/mco-actes-ccam-par-etablissements/open-ccam-2021. Accessed 5 Oct 2022.
    1. Ayed T, Rannen R, Naili K, Sokkah M, Gabsi S. [Risk factors for secondary cataract: a case-control study with multivariate analysis] J Fr Ophtalmol. 2002;25:615–20. - PubMed
    1. Benzerroug M, Milazzo S. La cataracte secondaire. EMC Ophtalmologie. 2014;11. - PubMed
    1. Royal College of Ophthalmologists. RCOphth NOD PCO Report 2021.pdf. https://www.nodaudit.org.uk/u/docs/20/rijbxkcubs/RCOphth%20NOD%20PCO%20R.... Accessed 5 Dec 2022.

Publication types

LinkOut - more resources